- Home
- ONCY vs GEG Comparison
ONCY vs GEG Comparison
Compare ONCY & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | GEG |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.1M | 87.5M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCY | GEG |
|---|---|---|
| Price | $1.02 | $2.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 683.5K | 41.8K |
| Earning Date | 11-12-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $23,112,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.66 |
| Revenue Growth | N/A | ★ 24.82 |
| 52 Week Low | $0.33 | $1.75 |
| 52 Week High | $1.51 | $3.51 |
Technical Indicators
Market Signals| Indicator | ONCY | GEG |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 38.98 |
| Support Level | $0.92 | $2.25 |
| Resistance Level | $1.06 | $2.74 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 77.46 | 28.57 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.